Can Selective Beta-Blockers Be Prescribed Safely for Hemodialysis Patients? A Retrospective Review

Michele A. Faulkner, A. J. Mears, Pat M. Adams, James T. Frock, Robert W. Dunlay

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Purpose: Cardiovascular disease is the leading cause of death in hemodialysis patients. Beta-blockers (gβ-blockers) have been shown to reduce cardiovascular morbidity and mortality in patients with coronary artery disease and heart failure. Available data demonstrate that end-stage renal disease patients are prescribed β-blockers much less often than are those with normal kidney function. The concern that these agents may lead to critical elevations in serum potassium (K) has led some nephrologists to avoid their use. This study evaluates the possible association between hyperkalemia and β-blocker use in stable hemodialysis patients. Methods: The records of 121 patients in an inner-city dialysis unit treated over a 3-month period were evaluated retrospectively. Patients taking β-blockers were compared to those who were not. Differences in age, incidence of diabetes mellitus, mean serum K level, use of β1-selective agents, dialysate concentration, and number and severity of hyperkalemic episodes were assessed. The highest K value recorded during the study period was used for each patient. Serum K levels greater than 6.5 mEq/L were defined as serious. Levels of this magnitude or greater were included in the analysis. Results: Only three patients were taking nonselective β-blockers. Twenty percent of patients in the β-blocker group had serum K levels greater than or equal to 6.5 mEq/L compared with 13.9% of those not taking β-blockers. A comparison of the two groups revealed no statistically significant difference in any of the parameters evaluated. Conclusion: The use of β1-selective agents does not appear to be associated with an increased incidence of serious hyperkalemia in hemodialysis patients. β-blockers should not be selectively withheld from hemodialysis patients for this reason.

Original languageEnglish
Pages (from-to)144-148
Number of pages5
JournalHospital Pharmacy
Volume39
Issue number2
StatePublished - Feb 2004

Fingerprint

Renal Dialysis
Dialysis
Dialysis Solutions
Medical problems
Potassium
Hyperkalemia
Serum
Incidence
Chronic Kidney Failure
Coronary Artery Disease
Cause of Death
Diabetes Mellitus
Cardiovascular Diseases
Heart Failure
Morbidity
Kidney
Mortality

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

Cite this

Can Selective Beta-Blockers Be Prescribed Safely for Hemodialysis Patients? A Retrospective Review. / Faulkner, Michele A.; Mears, A. J.; Adams, Pat M.; Frock, James T.; Dunlay, Robert W.

In: Hospital Pharmacy, Vol. 39, No. 2, 02.2004, p. 144-148.

Research output: Contribution to journalReview article

@article{6a6f4d4c085c4b50af1ba99b72248562,
title = "Can Selective Beta-Blockers Be Prescribed Safely for Hemodialysis Patients? A Retrospective Review",
abstract = "Purpose: Cardiovascular disease is the leading cause of death in hemodialysis patients. Beta-blockers (gβ-blockers) have been shown to reduce cardiovascular morbidity and mortality in patients with coronary artery disease and heart failure. Available data demonstrate that end-stage renal disease patients are prescribed β-blockers much less often than are those with normal kidney function. The concern that these agents may lead to critical elevations in serum potassium (K) has led some nephrologists to avoid their use. This study evaluates the possible association between hyperkalemia and β-blocker use in stable hemodialysis patients. Methods: The records of 121 patients in an inner-city dialysis unit treated over a 3-month period were evaluated retrospectively. Patients taking β-blockers were compared to those who were not. Differences in age, incidence of diabetes mellitus, mean serum K level, use of β1-selective agents, dialysate concentration, and number and severity of hyperkalemic episodes were assessed. The highest K value recorded during the study period was used for each patient. Serum K levels greater than 6.5 mEq/L were defined as serious. Levels of this magnitude or greater were included in the analysis. Results: Only three patients were taking nonselective β-blockers. Twenty percent of patients in the β-blocker group had serum K levels greater than or equal to 6.5 mEq/L compared with 13.9{\%} of those not taking β-blockers. A comparison of the two groups revealed no statistically significant difference in any of the parameters evaluated. Conclusion: The use of β1-selective agents does not appear to be associated with an increased incidence of serious hyperkalemia in hemodialysis patients. β-blockers should not be selectively withheld from hemodialysis patients for this reason.",
author = "Faulkner, {Michele A.} and Mears, {A. J.} and Adams, {Pat M.} and Frock, {James T.} and Dunlay, {Robert W.}",
year = "2004",
month = "2",
language = "English",
volume = "39",
pages = "144--148",
journal = "Hospital Pharmacy",
issn = "0018-5787",
publisher = "Facts and Comparisons",
number = "2",

}

TY - JOUR

T1 - Can Selective Beta-Blockers Be Prescribed Safely for Hemodialysis Patients? A Retrospective Review

AU - Faulkner, Michele A.

AU - Mears, A. J.

AU - Adams, Pat M.

AU - Frock, James T.

AU - Dunlay, Robert W.

PY - 2004/2

Y1 - 2004/2

N2 - Purpose: Cardiovascular disease is the leading cause of death in hemodialysis patients. Beta-blockers (gβ-blockers) have been shown to reduce cardiovascular morbidity and mortality in patients with coronary artery disease and heart failure. Available data demonstrate that end-stage renal disease patients are prescribed β-blockers much less often than are those with normal kidney function. The concern that these agents may lead to critical elevations in serum potassium (K) has led some nephrologists to avoid their use. This study evaluates the possible association between hyperkalemia and β-blocker use in stable hemodialysis patients. Methods: The records of 121 patients in an inner-city dialysis unit treated over a 3-month period were evaluated retrospectively. Patients taking β-blockers were compared to those who were not. Differences in age, incidence of diabetes mellitus, mean serum K level, use of β1-selective agents, dialysate concentration, and number and severity of hyperkalemic episodes were assessed. The highest K value recorded during the study period was used for each patient. Serum K levels greater than 6.5 mEq/L were defined as serious. Levels of this magnitude or greater were included in the analysis. Results: Only three patients were taking nonselective β-blockers. Twenty percent of patients in the β-blocker group had serum K levels greater than or equal to 6.5 mEq/L compared with 13.9% of those not taking β-blockers. A comparison of the two groups revealed no statistically significant difference in any of the parameters evaluated. Conclusion: The use of β1-selective agents does not appear to be associated with an increased incidence of serious hyperkalemia in hemodialysis patients. β-blockers should not be selectively withheld from hemodialysis patients for this reason.

AB - Purpose: Cardiovascular disease is the leading cause of death in hemodialysis patients. Beta-blockers (gβ-blockers) have been shown to reduce cardiovascular morbidity and mortality in patients with coronary artery disease and heart failure. Available data demonstrate that end-stage renal disease patients are prescribed β-blockers much less often than are those with normal kidney function. The concern that these agents may lead to critical elevations in serum potassium (K) has led some nephrologists to avoid their use. This study evaluates the possible association between hyperkalemia and β-blocker use in stable hemodialysis patients. Methods: The records of 121 patients in an inner-city dialysis unit treated over a 3-month period were evaluated retrospectively. Patients taking β-blockers were compared to those who were not. Differences in age, incidence of diabetes mellitus, mean serum K level, use of β1-selective agents, dialysate concentration, and number and severity of hyperkalemic episodes were assessed. The highest K value recorded during the study period was used for each patient. Serum K levels greater than 6.5 mEq/L were defined as serious. Levels of this magnitude or greater were included in the analysis. Results: Only three patients were taking nonselective β-blockers. Twenty percent of patients in the β-blocker group had serum K levels greater than or equal to 6.5 mEq/L compared with 13.9% of those not taking β-blockers. A comparison of the two groups revealed no statistically significant difference in any of the parameters evaluated. Conclusion: The use of β1-selective agents does not appear to be associated with an increased incidence of serious hyperkalemia in hemodialysis patients. β-blockers should not be selectively withheld from hemodialysis patients for this reason.

UR - http://www.scopus.com/inward/record.url?scp=1042291169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1042291169&partnerID=8YFLogxK

M3 - Review article

VL - 39

SP - 144

EP - 148

JO - Hospital Pharmacy

JF - Hospital Pharmacy

SN - 0018-5787

IS - 2

ER -